Dear Valued Customers and Partners,
As we approach the close of this year, we at ExSyn would like to extend our heartfelt gratitude for your trust, collaboration, and continued support. Your confidence in our products and services has been the driving force behind our growth and success.
The relationships we have built with you are at the core of everything we do, and we deeply appreciate the opportunity to serve and work alongside you. Looking ahead to the new year, we are excited to strengthen these bonds further, explore new opportunities together, and continue delivering value that supports your goals.
Thank you once again for being an integral part of our journey.
We wish you and your teams a prosperous, healthy, and fulfilling year ahead!
Warm regards,
The ExSyn Team
Today we announce that Exim is rebranding as ExSyn. We are presenting a new brand identity and website as a reflection of our relentless transformation over the course of 30 years serving the pharma and chemical industries. The new brand builds upon our core strengths as a sourcing company and captures our most essential duty: helping improve people’s health and lives.
Pyrazinamide is a first-line antitubercular drug used in combination therapy for the treatment of tuberculosis (TB). It is a synthetic pyrazine derivative and acts as a prodrug, which is converted into its active form (pyrazinoic acid) inside Mycobacterium tuberculosis.
Stakeholders are being encouraged to weigh in on the European Chemicals Agency (ECHA) 60-day public consultation period related to a planned ban on per-and-polyfluoroalkyl (PFAS) substances, also known as forever chemicals.
6-Bromopyridine-2,3-diamine is a heterocyclic organic compound belonging to the class of substituted pyridines. It is used mainly as an intermediate in pharmaceuticals and agrochemicals.